George Eric Davis sold $1.6M of BMRN
EVP, Chief Legal Officer at BIOMARIN PHARMACEUTICAL INC. 26,061 shares at an average of $61.36, traded Feb 26, 2026, filed Feb 26, 2026.
Score components
- +15RoleOfficer
- +25Trade size$1.6M at market
- +10Share of holdings soldSold 26% of holdings
- +15Cluster3 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -11.4%, 3m -13.7%, 6m +6.8%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001628280-26-012533, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 25, 2026 | AGrant or award Common Stock | +6,177 | $0.00 | $0 | 89,467 | Feb 26, 2026 |
| Feb 25, 2026 | AGrant or award Common Stock | +6,675 | $0.00 | $0 | 96,142 | Feb 26, 2026 |
| Feb 25, 2026 | AGrant or award Common Stock | +2,372 | $0.00 | $0 | 98,514 | Feb 26, 2026 |
| Feb 26, 2026 | SOpen-market sale Common Stock | -26,061 | $61.36 | $1.6M | 72,453 | Feb 26, 2026 |
Related signals
Other insiders at BIOMARIN PHARMACEUTICAL INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 45Moderate | BMRNsell BIOMARIN PHARMACEUTICAL INC | George Eric Davis EVP, Chief Legal Officer | $1.2M 17,557 shares | -22% | |
| 27Weak | BMRNsell BIOMARIN PHARMACEUTICAL INC | Gregory R Friberg EVP, Chief R&D Officer | $177k 3,281 shares | -6% | |
| 60Notable | BIOMARIN PHARMACEUTICAL INC | Charles Greg Guyer EVP, Chief Technical Officer | $997k 16,486 shares | -17% | |
| 51Moderate | BIOMARIN PHARMACEUTICAL INC | Gregory R Friberg EVP, Chief R&D Officer | $382k 6,326 shares | -14% | |
| 10Weak | BIOMARIN PHARMACEUTICAL INC | Erin Burkhart GVP, Chief Accounting Officer | $106k 1,786 shares | -11% | |
| 0Weak | BIOMARIN PHARMACEUTICAL INC | Cristin Hubbard EVP, Chief Commercial Officer | $18k 273 shares | -1% | |
| 13Weak | BIOMARIN PHARMACEUTICAL INC | Erin Burkhart GVP, Chief Accounting Officer | $93k 1,295 shares | -7% | |
| 41Moderate | BIOMARIN PHARMACEUTICAL INC | Charles Greg Guyer EVP, Chief Technical Officer | $501k 7,034 shares | -7% | |
| 12Weak | BIOMARIN PHARMACEUTICAL INC | Erin Burkhart GVP, Chief Accounting Officer | $92k 1,344 shares | -9% | |
| 30Weak | BMRNsell BIOMARIN PHARMACEUTICAL INC | Charles Greg Guyer EVP, Chief Technical Officer | $350k 5,278 shares | -7% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.